PT - JOURNAL ARTICLE AU - Radzi M Noh AU - Sowmya Venkatasubramanian AU - Shruti Daga AU - Jeremy Langrish AU - Nicholas L Mills AU - Ninian N Lang AU - Ethan Hoffmann AU - Brian Waterhouse AU - David E Newby AU - Brian M Frier TI - Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus AID - 10.1136/openhrt-2017-000647 DP - 2017 Sep 01 TA - Open Heart PG - e000647 VI - 4 IP - 2 4099 - http://openheart.bmj.com/content/4/2/e000647.short 4100 - http://openheart.bmj.com/content/4/2/e000647.full SO - Open Heart2017 Sep 01; 4 AB - Background The cardiometabolic effects of SRT2104, a novel SIRT1 activator, were investigated in people with type 2 diabetes mellitus (T2DM).Methods Fifteen adults with T2DM underwent a randomised, double-blind, placebo-controlled cross-over trial and received 28 days of oral SRT2104 (2.0 g/day) or placebo. Forearm vasodilatation (measured during intrabrachial bradykinin, acetylcholine and sodium nitroprusside infusions) as well as markers of glycaemic control, lipid profile, plasma fibrinolytic factors, and markers of platelet-monocyte activation, were measured at baseline and at the end of each treatment period.Results Lipid profile and platelet-monocyte activation were similar in both treatment arms (p>0.05 for all). Forearm vasodilatation was similar on exposure to acetylcholine and sodium nitroprusside (p>0.05, respectively). Bradykinin-induced vasodilatation was less during treatment with SRT2104 versus placebo (7.753vs9.044, respectively, mean difference=−1.291,(95% CI −2.296 to −0.285, p=0.012)). Estimated net plasminogen activator inhibitor type 1 antigen release was reduced in the SRT2104 arm versus placebo (mean difference=−38.89 ng/100 mL tissue/min, (95% CI −75.47, to –2.305, p=0.038)). There were no differences in other plasma fibrinolytic factors (p>0.05 for all).After 28 days, SRT2104 exposure was associated with weight reduction (−0.93 kg (95% CI −1.72 to −0.15), p=0.0236), and a rise in glycated haemoglobin (5 mmol/mol or 0.48% (0.26 to 0.70), p=0.004)Conclusions In people with T2DM, SRT2104 had inconsistent, predominantly neutral effects on endothelial and fibrinolytic function, and no discernible effect on lipids or platelet function. In contrast, weight loss was induced along with deterioration in glycaemic control, suggestive of potentially important metabolic effects.Clinical trial registration NCT01031108; Results.